YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy

Basit Öğe Kaydı
dc.contributor.authorArslan, Ugur
dc.contributor.authorUral, Onur
dc.contributor.authorFindik, Duygu
dc.date.accessioned2020-03-26T17:28:30Z
dc.date.available2020-03-26T17:28:30Z
dc.date.issued2008
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractLamivudine resistance is a result of mutations in YMDD motif in which rt203-206(th) codons (Y: tyrosine; M: methionin; D: aspartic acid; D: aspartic acid) of reverse trancriptase; the catalytic part of hepatitis B polymerase enzyme, takes place. In this study we aimed to show the YMDD motif variants in chronic hepatitis B patients who have presumably developed lamivudine resistance due to viral polymerase gene mutation during lamivudine therapy. Twenty lamivudine treated patients were included in the study, and HBV-DNA was extracted from the sera of the patients by using extraction kit (Invisorb, Instant Spin DNA/RNA Virus Mini Kit, Germany). A line probe assay (INNO-LIPA HBV DR; INNOGENETICS N.V, Ghent, Belgium) was used to determine YMDD motif variants at viral polymerase gene fragment in HBV-DNA samples of these patients and evaluated colorimetrically. In 12 (60%) patients' samples YMDD motif variants were detected leading to lamivudin resistance. Eleven (91.6%) of the 12 samples having motif variants were YMDD variant and wild-type combination. While YMDD + YIDD combination was determined in only one specimen, YMDD + YVDD combination was determined in six. Mixed combination of YMDD + YVDD + YIDD were detected in four samples. In 8 (66.6%) HBV-DNA samples YMDD variants were accompanied with L180M variants. It can be concluded that determination of genotypic resistance before the expression of phenotypic resistance during lamivudin therapy is important since addition of adefovir to the therapy at an early stage will prevent the occurence of hepatitis with mutant species. Thus lamivudin resistance should be followed up regularly in all of the chronic hepatitis B patients under lamivudin therapy.en_US
dc.identifier.endpage450en_US
dc.identifier.issn0374-9096en_US
dc.identifier.issue3en_US
dc.identifier.pmid18822888en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage445en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/22790
dc.identifier.volume42en_US
dc.identifier.wosWOS:000258416900009en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isotren_US
dc.publisherANKARA MICROBIOLOGY SOCen_US
dc.relation.ispartofMIKROBIYOLOJI BULTENIen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjecthepatitis B virusen_US
dc.subjectline probe assay (LIPA)en_US
dc.subjectresistanceen_US
dc.subjectYMDD mutationen_US
dc.titleYMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu